MiraDx’s latest study highlights the potential for their PROSTOX ultra test to significantly improve treatment personalization for high-risk prostate cancer patients. As the findings will be showcased at the upcoming ASTRO Annual Meeting, this research could reshape therapeutic strategies in oncology, making it a pivotal moment for both clinicians and patients.
LOS ANGELES–(BUSINESS WIRE)– #ASTRO2025–MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 27 to October 1, 2025, in San Francisco, Calif. The study, conducted by UCLA and other leading academic institutions, used MiraDx’s PROSTOX ultra test to identify prostate cancer patients at higher risk of late
Source: Original Press Release